BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

BioCryst Pharma (BCRX) Reports In-Line Q4 EPS, Revenues MissMarch 4, 2019 7:13 AM BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 DevelopmentMarch 4, 2019 7:01 AM